BioMarin Buys ZyStor For $115M

Luke Timmerman8/18/10

BioMarin Pharmaceutical (NASDAQ: BMRN), the Novato, CA-based maker of drugs for rare diseases, said it has agreed to acquire Milwaukee, WI-based ZyStor Therapeutics for $22 million upfront, plus another $93 million if certain milestones are met, bringing the total value of  the deal to $115 million. ZyStor is developing enzyme replacement therapies for lysosomal storage disorders. Its lead drug candidate is for the treatment of Pompe disease.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.